Halozyme Announces argenx Received Approval In Japan For VYVDURA Co-Formulated With ENHANZE For Generalized Myasthenia Gravis
Portfolio Pulse from Benzinga Newsdesk
Halozyme Therapeutics, Inc. announced that argenx has received approval in Japan for VYVDURA co-formulated with Halozyme's ENHANZE technology for the treatment of generalized myasthenia gravis. This approval could potentially lead to increased revenue for Halozyme from its ENHANZE technology.

January 18, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme's ENHANZE technology is part of the newly approved VYVDURA for myasthenia gravis in Japan, which may increase Halozyme's revenue streams.
The approval of VYVDURA co-formulated with Halozyme's ENHANZE technology in Japan is a significant regulatory milestone that could lead to increased usage and sales, directly benefiting Halozyme through licensing or royalty revenues. Given the size of the Japanese market and the potential for expanded use in other indications, this approval is likely to have a positive short-term impact on Halozyme's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90